Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Co. joined several other investors in a Series A round for a Boston biotech co-founded by the Longwood Fund that's developing a drug for a rare type of blood cancer.

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Morgan Stanley has hired senior dealmaker David Kostel as the vice chairman of its health-care investment banking group, ...

We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to ...

GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

Additionally, other companies like Scorpion Therapeutics are developing similar compounds, potentially narrowing Relay’s window of opportunity. Despite these challenges, analysts believe that ...

We recently published a list of Starter Stock Portfolio 12 Safe Stocks to Buy. In this article, we are going to take a look ...

Additionally, other companies like Scorpion Therapeutics are developing similar compounds, potentially narrowing Relay’s window of opportunity. Despite these challenges, analysts believe that Relay’s ...

These begin from DICE Therapeutics in June of 2023 to the most recent, Scorpion Therapeutics, in January 2025. Analysts have a consensus on Eli Lilly and Company (NYSE:LLY) twelve-month trading ...